Companies / South Africa
South African Activists Seek ARV Price Cut
June 2006 | Company Finance AlertSouth Africa's Treatment Action Campaign (TAC) has warned that it may take US drugmaker Merck & Co to the country's Competition Commission in order to force the company to hand out more generic licenses for its patented ARV efavirenz. Presently, Merck has only granted one generic license for the drug, to South Africa's Aspen Pharmacare. This in effect has had the impact of merely transferring Merck's monopoly over the drug to another company.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
